rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Phase 1

Completed

• Conditions: Acid Maltase Deficiency Disease; Glycogen Storage Disease Type II; Pompe Disease; Glycogenosis 2

• Registration Number: NCT00053573
• Lead Sponsor: Genzyme, a Sanofi Company

Brief Summary

Glycogen Storage Disease Type II ("GSD-II"; also known as Pompe disease) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with GSD-II, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. This study is being conducted to evaluate the safety and effectiveness of recombinant human acid alpha-glucosidase (rhGAA) as a potential enzyme replacement therapy for GSD-II. Patients diagnosed with infantile-onset GSD-II who are greater than 6 months old, but less than or equal to 36 months old will be studied.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-01-31
• Study Start: 2003-02
• Study First Submitted QC: 2003-02-01
• Study First Posted: 2003-02-03
• Primary Completion: 2006-07
• Study Completion: 2006-11
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-04
• Last Update Posted: 2014-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• The patient or the patient's legal guardian(s) must provide written informed consent prior to any study-related procedures being performed
• The patient must have a clinical diagnosis of infantile GSD-II as defined by: (a) the patient has/had documented (in a medical record) onset of symptoms compatible with GSD-II by 12 months of age; (b) the patient has documented GAA deficiency as illustrated by an endogenous GAA activity less than or equal to 2% of the mean of the normal range as assessed in cultured skin fibroblasts; AND (c) the patient has a Left Ventricular Mass Index greater than 2 standard deviations above the mean for age
• The patient is greater than 6 months old and less than or equal to 36 months old at the time of the first dose of rhGAA
• The patient and his/her legal guardian(s) must have the ability to comply with the clinical protocol

Exclusion Criteria

• Signs and symptoms of cardiac failure and an ejection fraction less than 40%
• Major congenital abnormality
• Clinically significant organic disease (with the exception of symptoms relating to GSD-II), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial or potentially decrease survival
• Use of any investigational product within 30 days prior to study enrollment
• Received enzyme replacement therapy with GAA from any source

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Evaluate the safety of Myozyme	52 weeks
PK profile of MZ	52 weeks
Determine proportion of patients alive over the course of treatment	52 weeks
PD profile of MZ	52 weeks

Trial Locations

Locations (6)

University of Florida College of Medicine; 🇺🇸 Gainesville, Florida, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Pediatrique Hopital de Brousse; 🇫🇷 Lyon, France

Rambam Medical Center; 🇮🇱 Haifa, Israel

Royal Manchester Children's Hospital; 🇬🇧 Manchester, United Kingdom